GLP-1 Clinical Relevance #42Contextual Information Background context; limited direct clinical applicability. ⚕ GLP-1 News | CED Clinic Clinical TrialObservational StudyPediatric ObesityInsulin ResistanceEndocrinologyChildren and AdolescentsCardiovascular RiskPancreatic Fat AccumulationMetabolic DysfunctionEctopic Fat DepositionInsulin SecretionCardiometabolic Health...
GLP-1 Receptor Agonists for Metabolic Health Management
GLP-1 Clinical Relevance #42Contextual Information Background context; limited direct clinical applicability. ⚕ GLP-1 News | CED Clinic Clinical ReviewObservational StudyMetabolic HealthPolyphenol CompoundsFamily MedicineAdults with ObesityInsulin Resistance ReductionAnti-inflammatory PathwayTart Cherry ExtractWeight Management InterventionHypertension...
GLP-1 Receptor Agonists: Semaglutide vs Tirzepatide
GLP-1 Clinical Relevance #43Contextual Information Background context; limited direct clinical applicability. ⚕ GLP-1 News | CED Clinic Clinical ComparisonObservational StudyHeart Failure with Preserved Ejection FractionSemaglutideCardiologyAdults with ObesityCardiovascular OutcomesAppetite RegulationTirzepatideGLP-1 Receptor AgonistHFpEF ManagementWeight...
GLP-1 Receptor Agonist Clinical Evidence and Safety
GLP-1 Clinical Relevance #44Contextual Information Background context; limited direct clinical applicability. ⚕ GLP-1 News | CED Clinic CommentaryObservational StudyWeight LossGLP-1 Receptor AgonistPrimary CareAdults with ObesitySocial Perception and StigmaAppetite RegulationSemaglutide and OzempicPatient Attitudes...
GLP-1 Receptor Agonist Hair Loss: Clinical Evidence Character count: 56
GLP-1 Clinical Relevance #45Moderate Clinical Relevance Relevant context for GLP-1 prescribers; interpret with care. ⚕ GLP-1 News | CED Clinic Clinical CommentaryObservational StudyHair LossSemaglutideEndocrinologyAdults with ObesityAdverse Event ReportingGLP-1 Receptor AgonistTirzepatideMedication Side EffectsOzempic...
GLP-1 Weight Loss: Prevent Rebound After Drug Discontinuation
GLP-1 Clinical Relevance #45Moderate Clinical Relevance Relevant context for GLP-1 prescribers; interpret with care. ⚕ GLP-1 News | CED Clinic CommentaryObservational StudyWeight Regain PreventionTirzepatideFamily MedicineAdults with ObesityWeight Rebound ManagementAppetite RegulationGLP-1 Discontinuation StrategyMetabolic...
GLP-1 Receptor Agonist: Beyond Appetite Suppression
GLP-1 Clinical Relevance #48Moderate Clinical Relevance Relevant context for GLP-1 prescribers; interpret with care. ⚕ GLP-1 News | CED Clinic CommentaryObservational StudyAppetite RegulationSemaglutideEndocrinologyAdults with ObesityWeight ManagementReward System SuppressionGLP-1 Receptor AgonistBehavioral EffectsOff-Label UseMedicare...
GLP-1 RA Therapy for IBD: Weight Loss and Clinical Outcomes
GLP-1 Clinical Relevance #47Moderate Clinical Relevance Relevant context for GLP-1 prescribers; interpret with care. ⚕ GLP-1 News | CED Clinic Clinical CommentaryObservational StudyInflammatory Bowel DiseaseGLP-1 Receptor AgonistGastroenterologyAdults with IBDWeight Loss and Metabolic...
Medical Cannabis Authorization Linked to Modestly Higher Heart Failure Risk in Large Canadian Cohort
Patients exposed to cannabis had a higher risk for the primary outcome with a hazard ratio of 1.15 (95% CI: 1.06–1.25), while incidence rates for ED visits/hospitalization due to HF were 5.87 per 1000 person-years in the cannabis group versus 5.14 per 1000 person-years in controls.
Medical Cannabis Authorization Linked to Modestly Higher Heart Failure Risk in Large Canadian Cohort
Patients exposed to cannabis had a higher risk for the primary outcome with a hazard ratio of 1.15 (95% CI: 1.06–1.25)… The results suggest a higher risk of heart failure-related events, including emergency department visits, hospitalizations, and outpatient consultations, among patients who were authorized cannabis for medical purposes.